Oncobesity News Posts

Despite soaring demand for GLP-1s, many eligible patients are unable to access these drugs for weight loss

Despite soaring demand for GLP-1s, many eligible patients are unable to access these drugs for weight loss

In just a few short years, glucagon-like peptide-1 (GLP-1) receptor agonists have surged in popularity across the United States, transforming from specialized treatments for type 2 diabetes into revolutionary therapeutics for weight management, cardiovascular health and other emerging uses. But not all populations are benefiting from this expansion. As GLP-1 use has increased, disparities in access to these drugs have widened significantly, according to a new study led by researchers at Boston University School of Public Health (BUSPH).

Read More »
Planning to Stop Taking a GLP-1? Here’s How to Maintain Weight Loss

Planning to Stop Taking a GLP-1? Here’s How to Maintain Weight Loss

Saturday, November 21 – Research shows that having an “exit strategy” after stopping at GLP-1 can help maintain your weight loss. coldsnowstorm · E+/Getty

A Cleveland Clinic study found that bariatric surgery and switching GLP-1 medications were associated with greater weight loss than discontinuing treatment entirely.

After two years, participants who underwent bariatric surgery lost an average of 28.2% of their body weight, compared with 16% among those who switched between semaglutide and tirzepatide and 4% among those who stopped GLP-1 treatment.

Read More »
$1B-plus deal takes Innogen’s approved GLP-1 abroad

$1B-plus deal takes Innogen’s approved GLP-1 abroad

Innogen Pharmaceuticals has struck a potential $1 billion-plus licensing deal with Abu Dhabi’s Arcera Life Sciences. The deal will take its China-approved GLP-1 Diabegone (efsubaglutide alfa) to markets in four regions. It extends the globalization of China-originated metabolic drugs beyond the usual U.S. and European licensing route.

Read More »

Inside Look at Vacations Geared Toward People on GLP-1s

Friday, November 20 – Along with focusing on diet and exercise, health and wellness resorts across the country are now catering to the millions of people using GLP-1 weight loss drugs like Ozempic, Zepbound, Wegovy and Mounjaro. The programs include cooking lessons, guided strength-training sessions, and health counseling about those weight loss medicines. NBC’s Vicky Nguyen reports for TODAY.

Read More »

Semaglutide may improve eating disorder symptoms and body image in adults seeking obesity treatment

Thursday, November 19 – Adults receiving semaglutide for obesity treatment experienced greater improvements in several measures of disordered eating, eating disorder symptoms and body image concerns compared with participants receiving placebo, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania. The study was published in the International Journal of Eating Disorders.

Read More »

Why don’t GLP‑1 obesity drugs work for everyone?

Thursday, November 19 – Medications like Ozempic and Wegovy, which contain semaglutide—a GLP‑1 receptor agonist that helps regulate blood sugar, appetite and body weight—have become household names and important pillars in obesity management for the medical profession.

Read More »

Tirzepatide moves more than half of treated teens below obesity threshold, new clinical trial reports

Wednesday, November 18 – Tirzepatide (Zepbound) is a once-weekly injectable medication that hits two targets at once. This dual-action drug mimics the effects of two natural gut hormones in the body—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Working together, these hormones keep blood sugar in check, slow the movement of food through the gut and signal the brain about fullness, which helps manage appetite and food intake.

Read More »

Ozempic and Mounjaro may have a surprising effect on your brain

Wednesday, November 18 – Blockbuster weight loss drugs like Ozempic and Mounjaro may do more than help people shed pounds, with growing evidence suggesting they could also influence brain health. Although studies have linked GLP-1 medications to a lower risk of dementia, major trials found that semaglutide did not slow Alzheimer’s disease. Scientists suspect these drugs may be more effective at preserving memory and thinking abilities in people with obesity or diabetes, especially before cognitive problems appear.

Read More »

Wegovy Reduces BMI in Kids With Obesity as Young as 6

Wednesday, November 18 – (MedPage Today) — NATIONAL HARBOR, Md. — Young children ages 6 to 11 years with obesity lost significant weight with the GLP-1 medication semaglutide (Wegovy), according to results from the phase III STEP Young trial.
At week 68, mean body…

Read More »

Ending Medicaid coverage for weight-loss drugs linked to sharp drop in GLP-1 use

Tuesday, November 17 – Medicaid prescriptions for weight loss–approved GLP-1 medications fell sharply after four states ended coverage of the drugs, according to a new study led by researchers at the University of Pittsburgh. The findings, published in JAMA, demonstrate how state coverage decisions can have an immediate and substantial effect on access to these medications.

Read More »

GLP-1s often contain untested additive combinations, study finds

Sunday, November 15 – Use of GLP-1 receptor agonist medications (GLP-1s) has skyrocketed in recent years, and many people are using “compounded” GLP-1 products: medicines that include GLP-1s as well as other active substances, some of which are not regulated by the FDA. A new study found that compounded GLP-1s now make up a large majority of weight-loss medicines, commonly containing vitamin B12 analogs that have not been tested for safety in combination with GLP-1s.

Read More »

Study of 750,000 pregnancies reveals a surprising twist about Ozempic and Wegovy

Saturday, November 14 – A study of more than 750,000 pregnancies found that early exposure to Ozempic, Wegovy, and similar drugs was not linked to increased pregnancy complications when used for weight loss, but was associated with a higher risk of premature birth when prescribed for diabetes. The surprising difference suggests that diabetes itself may be driving the risk, although researchers caution that the drugs’ safety during pregnancy remains uncertain.

Read More »

Pfizer bero hero Blackstone funds GLP-1 run to $1.5B

Saturday, November 14 – Up to $1.5 billion from Blackstone Life Sciences for Pfizer Inc.’s push with GLP-1 prospect berobenatide (bero) will also help with the looming patent cliff, too, as the pharma giant faces loss of exclusivity for factor Xa inhibitor anticoagulant Eliquis (apixaban) in the spring of 2028.

Read More »

FDA Initiates Labeling Changes for GLP-1s Due to Rare But Serious Eye Disease Risk

Thursday, November 12 – A rare eye disease has been added to the growing list of side effects linked to GLP-1s, adding a second eye warning to several labels. Michael Siluk/UCG/Universal Images Group via Getty Images

The FDA is requiring new warnings on Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1s about a potential increase in the risk of a rare eye condition that can cause sudden vision loss.

Regulators in the European Union, United Kingdom, and Australia have added similar warnings, mostly for semaglutide.

Read More »

Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November

Thursday, November 12 – Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about the risk of a rare eye condition that can lead to vision loss; and the agency is set to decide on no fewer than 11 therapies this month, including closely watched applications from Summit Therapeutics, Vertex and Capricor Therapeutics.

Read More »

GLP-1 Pill Shows Benefit in Sleep Apnea

Thursday, November 12 – (MedPage Today) — The oral GLP-1 receptor agonist orforglipron (Foundayo) improved sleep-disordered breathing in patients with moderate-to-severe obstructive sleep apnea and overweight or obesity, two phase III trials showed.
For the treatment…

Read More »